Peptide MegaPools Approach to Evaluate the Dengue-Specific CD4 and CD8 T-Cell Response
Pathogens · 2025
DOI: 10.3390/pathogens15010005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2025. Verfasst von Marta Tiberi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Unit, National Institute for Infectious Diseases "L. Spallanzani"-IRCCS, 00149 Rome, Italy. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Dengue Virus, Dengue, CD4-Positive T-Lymphocytes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Ministero della Salute, Italian Ministry of Health, Ricerca Corrente Linea 1.
Abstract (Originalsprache)
Background
Being central players in the adaptive immunity, the study of T-cell responses is crucial in both natural infections and vaccine-induced immunity. In this study, we assessed the antigen-specific T-cell responses to dengue virus (DENV) to identify the most immunogenic antigen for evaluating dengue-specific T-cell responses.
Methods
Patients with dengue disease and subjects vaccinated with the QDENGA (TAK-003) vaccine (before and three months after vaccination) were enrolled. The T-cell-specific response was measured by ELISPOT and Activation Induced Markers (AIM) assay following PBMC stimulation either with DENV1-4 CD4 and CD8 MegaPools (MP) or serotype-specific DENV peptide pools at different concentrations.
Results
We found that both DENV1-4 CD4 MP (at 1 µg/mL) and CD8 MP (at 5 µg/mL), which encompass all four DENV serotypes, elicited specific T-cell responses in patients with dengue infection independent of the infecting serotype. In contrast, selected serotype-specific DENV peptide pools have a lower ability to induce a measurable T-cell response. Moreover, DENV1-4 CD4 and CD8 MPs, at the highest concentrations, are suitable candidates to evaluate the dengue-specific T-cell response in vaccinated subjects.
Conclusions
These findings support the use of the MP approach to investigate dengue-specific T-cell response to monitor the response during the infection and after vaccine administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Research Unit, National Institute for Infectious Diseases "L. Spallanzani"-IRCCS, 00149 Rome, Italy.
- Professioni Sanitarie Tecniche, National Institute for Infectious Diseases "L. Spallanzani"-IRCCS, 00149 Rome, Italy.
- Clinical Disease Unit, National Institute for Infectious Diseases "L. Spallanzani"-IRCCS, 00149 Rome, Italy.
- Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
- Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego (UCSD), La Jolla, CA 92093, USA.
ORCID-Profile: Marta Tiberi, Linda Petrone, Valentina Vanini, Alessandra D'Abramo, Patrizia De Marco, Alba Grifoni, Daniela Weiskopf, Alessandro Sette, Emanuele Nicastri, Delia Goletti
Förderung
- NIAID NIH HHS
- Ministero della Salute
- Italian Ministry of Health, Ricerca Corrente Linea 1
- NIAID/NIH
Zitieren
APA
Tiberi, M., Petrone, L., Salmi, A., Vanini, V., Cuzzi, G., D'Abramo, A., De Marco, P., Grifoni, A., Weiskopf, D., Sette, A., Nicastri, E., & Goletti, D. (2025). Peptide MegaPools Approach to Evaluate the Dengue-Specific CD4 and CD8 T-Cell Response. Pathogens. https://doi.org/10.3390/pathogens15010005
Vancouver
Tiberi M, Petrone L, Salmi A, Vanini V, Cuzzi G, D'Abramo A, et al. Peptide MegaPools Approach to Evaluate the Dengue-Specific CD4 and CD8 T-Cell Response. Pathogens. 2025. doi:10.3390/pathogens15010005
BibTeX
@article{Tiberi2025,
author = {Tiberi, Marta and Petrone, Linda and Salmi, Andrea and Vanini, Valentina and Cuzzi, Gilda and D'Abramo, Alessandra and De Marco, Patrizia and Grifoni, Alba and Weiskopf, Daniela and Sette, Alessandro and Nicastri, Emanuele and Goletti, Delia},
title = {Peptide MegaPools Approach to Evaluate the Dengue-Specific CD4 and CD8 T-Cell Response},
journal = {Pathogens},
year = {2025},
doi = {10.3390/pathogens15010005}
}
EUVIMED